MAPT and Alzheimer disease: Conversely, in tauopathies such as AD or other dementia, the production of p-tau, C- or N terminal truncated tau species are specifically increased, reflecting underlying neurofibrillary pathology and the formation of post translationally modified species which accumulate in brain and can be also detected in biological fluid (117–119).